Pregled bibliografske jedinice broj: 617297
Hot off the breath : Mortality as a primary and-point in IPF treatment trials : the best is the enemy of the good
Hot off the breath : Mortality as a primary and-point in IPF treatment trials : the best is the enemy of the good // Thorax, 67 (2012), 11; 938-940 doi:10.1136/thoraxjnl-2012-202580 (podatak o recenziji nije dostupan, uvodnik, stručni)
CROSBI ID: 617297 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Hot off the breath : Mortality as a primary and-point in IPF treatment trials : the best is the enemy of the good
Autori
Wells, A.U. ; ... ; Peroš-Golubičić, Tatjana ; ... ; Xaubet, A.
Izvornik
Thorax (0040-6376) 67
(2012), 11;
938-940
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, uvodnik, stručni
Ključne riječi
Idiopathic pulmonary fibrosis; end-point in clinical trials
Sažetak
The proposal that the mortality should be a primary end-point in IPF treatment trials is discussed. The European IPF consensu group is vehemently opposed to the idea that the mortality data should be required for drug registration in IPF. The mortality is viewed as a highly unsuitable primary end-point in phase three trials ; unacceptable to patients and likely to deter pharmaceutical companies from developing new IPF therapies.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
European IPF Consensus Group.
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
